Special Issue "In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research 2023"
Deadline for manuscript submissions: 20 April 2024 | Viewed by 4395
Interests: radiochemistry; nuclear medicine; medicinal chemistry; organic synthesis; molecular imaging
Special Issues, Collections and Topics in MDPI journals
Molecular imaging can provide the real-time noninvasive visualization, characterization, and quantification of biological processes at the molecular level in intact living subjects. Nuclear molecular imaging has been receiving a great deal of attention due to its high sensitivity and noninvasive imaging profile. This unique imaging modality enables scientists to study in vivo functional information that is usually challenging or impossible to evaluate using other imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT). Furthermore, radioisotope-labeled imaging agents can detect the onset of abnormalities before any morphological changes. With the emerging use of precision medicine and personalized treatment in patient management, nuclear molecular imaging is at the forefront of the trend in aiding diagnosis, monitoring disease progression, and evaluating therapeutic responses.
This special issue of Pharmaceuticals invites both original research and review articles related to in vivo nuclear imaging in drug development and pharmacological research, and we welcome submissions on the following topics: 1) identification and validation of in vivo biomarkers by nuclear molecular imaging; 2) evaluation of on-target and off-target effects, receptor occupancy, and biodistribution information of the radiotracers; 3) in vivo biorthogonal reaction involving radioisotopes to probe disease mechanisms; 4) determining pharmacokinetics and pharmacodynamics as well as metabolic profiles; 5) dosimetry studies, kinetic modeling of radiotracers in pre-clinical research and clinical investigation; and 6) bench-to-bedside clinical translation of radiotracers.
Dr. Xuyi Yue
Dr. Kiran Kumar Solingapuram Sai
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nuclear molecular imaging
- drug development
- in vivo application
- nuclear precision medicine